Platelets in the Single Digits: IVIG Now, and a Harder Choice for What Comes After
Her platelet count is in the single digits and she's bleeding from her gums. High-dose steroids, which usually work, haven't touched it. The disagreement is about the next several hours, and separately, the next several months.
N.E., a 22-year-old woman in her final semester of college, was admitted two days ago with a platelet count of 6,000/µL, gum bleeding, and scattered petechiae, on a background of SLE diagnosed at age 19 with prior mucocutaneous and articular disease only, no prior hematologic involvement. She was started on IV methylprednisolone 1g daily on admission for presumed lupus-associated immune thrombocytopenia after a bone marrow biopsy showed normal megakaryocytes and no infiltrative process, and forty-eight hours later her platelet count has moved only to 9,000/µL — a real, inadequate response by any threshold, not simply a slow but working one. She has final exams in ten days, and asked between rounds this morning whether she would be well enough to sit for them. Nothing in her chart records whether she carries antiphospholipid antibodies; the panel has not been sent, and in lupus-associated thrombocytopenia, where antiphospholipid positivity is common rather than incidental, that blank is not a neutral one.
A platelet count this low with active mucosal bleeding is not a number that tolerates waiting for a slower-acting therapy to take effect; the immediate risk is a spontaneous intracranial or gastrointestinal hemorrhage, and that risk is what has to be addressed in the next several hours, separate from whatever gets chosen as her longer-term second-line agent. IVIG works within twenty-four to forty-eight hours through Fc-receptor blockade, buying real time regardless of what happens next; rituximab, the more commonly used durable second-line option in lupus-associated cytopenias, generally takes two to six weeks to produce a meaningful platelet response, which makes it a reasonable durable strategy but not, on its own, an answer to tonight's bleeding. Eltrombopag works through an entirely different mechanism — stimulating platelet production directly rather than reducing autoimmune platelet destruction — and Kumar and colleagues' 2019 single-center series of twelve steroid-refractory lupus ITP patients reported a median response inside about eight days, fast enough to matter here. That evidence is twelve patients deep, not a randomized trial, and it cuts in a second direction the mechanism makes unavoidable: a drug whose entire purpose is to drive the platelet count up is a prothrombotic drug, and Garra and colleagues reported catastrophic antiphospholipid syndrome in two lupus patients started on eltrombopag, both triple-positive for antiphospholipid antibodies, neither with any prior thrombosis. Her own antiphospholipid status is unknown, which is what turns a question about immunosuppression burden into a question about which test has to come back first.
Inpatient consult, active bleeding, refractory to steroids
Six thousand platelets with active gum bleeding, and forty-eight hours of high-dose steroids has barely moved the number — that's an inadequate response, not a slow one. IVIG works through Fc-receptor blockade within twenty-four to forty-eight hours. I'd start it tonight; the immediate risk is a spontaneous bleed we can't afford to wait out.
I'd add rituximab today as well, in parallel rather than waiting to see if IVIG alone gets her through this. It's the more durable second-line option in lupus-associated cytopenias, but it takes two to six weeks to show a real platelet response — if we wait to start it until after IVIG's effect starts fading, we've built in a second delay we didn't need.
I want to be clear rituximab isn't doing anything for tonight's bleeding — it's a decision about not losing more time on the next several weeks while we're already in the room.
Both of those are reasonable, and the immunosuppression stack you're building is real — high-dose steroids, IVIG and rituximab at once in a 22-year-old. Eltrombopag is the obvious way out of that, because it stimulates platelet production rather than suppressing the immune process destroying them, and Kumar's lupus ITP series got responses in a median of about eight days. I was going to argue for adding it tonight.
I'm not going to, and the reason is that we don't know her antiphospholipid status. Garra reported two lupus patients who developed catastrophic antiphospholipid syndrome after starting eltrombopag, both triple-positive, neither with any prior clot — and lupus ITP is one of the presentations where antiphospholipid positivity clusters. IVIG is independently prothrombotic too, so what's being proposed is two procoagulant exposures and a rising platelet count in someone whose clotting risk nobody has measured. Send the panel tonight with everything else; it doesn't delay the IVIG or the rituximab by a minute. If she's negative, eltrombopag is a good idea and I'll say so tomorrow. If she's triple-positive, we would have been adding it blind.
Agreed: start IVIG tonight for the immediate bleeding risk, start rituximab today in parallel as the durable second-line agent, send an antiphospholipid panel tonight alongside them, and hold eltrombopag until it returns rather than adding a prothrombotic agent to a prothrombotic one in a patient whose clotting risk has never been measured. Continue methylprednisolone unchanged.
Not agreed: whether starting rituximab today was the right level of aggressiveness, or whether IVIG alone deserved a short trial first — the hematologist's narrower focus on tonight's bleeding wasn't overruled, only broadened once the rheumatologist argued the group was already in the room and shouldn't spend the visit on a single intervention. Also unresolved, and named rather than smoothed over: whether the antiphospholipid panel should have been sent at admission two days ago, in which case tonight's decision about eltrombopag would already have an answer instead of a hold.